I'm holding, 98% down, won't average down neither. The R/S will commence. Would be wise to get a accountant and show him the numbers. See if he see light at the end of te tunnel. They're is no light, the defector is building rapidly, forget anything else, but concentrate on the number side alone, we can't reverse this train, as a businessman, it would be wise to R/S, or diluted. Indian is not happening, China has no revenues, they would've been in place by now. Current progress in US will not be sufficient enough to brake the current ration now. You would need some heavy revenue and be possibly green to offset the liabilities and overhead. It is not mathematically possible at the current rate. The future is not too swift, and with what I've uncover, I have no faith into it. I'm willing to show you personally what I hold, but then you will be willing to tell me who you are. My Facebook page has a window to whom I'am, I have nothing to hide, nor fear. I'm not even upset the fact that I'm wiped out, just in disbelieve EWSI was not different and another OTC. I worked my ads off protecting the imagige of this company, for what, lol. I learned not to trust these pinky plays, funny how the time spent here teaches you how the game is played. Look at the pumpers in ihub on the board now. They're all swing-traders- mixed with flippers, no longs. Except a few which I kinda know, and they're hurting hard. It's a shame, cause I trusted this company, but you live and learned, it's a lost in my eyes, I got over it. But I WILL NOT LET THEM BRAIN WASH HARD WORKING PEOPLE OUT THEIR HARD EARN MONEY, that will be my contribution. Ask Reivax, he also was a die-hard, but he saw the reality of the matter, maybe the only thing left is insider, I could be swimming in a pool of them. On FB I wasn't the only one who's upset, many others as well, but you don't know their names here. Anyone feels they were lied and scammed, PM your email address and info, I'll put you on the list to see if we could recover here, I won't disclose any information. One thing about me, is that I have many relationships here with allot of you guys on the private message, and I've never disclosed any members chats or personal opinions on any board, I've always been commited to trust and friendship loyalty with you all, and no one could taint with that statement, no one. My beef is with the company, not with my fellow friends, loyalty and trust, unless you brake that trust with me.
I'm holding, 98% down, won't average down neither. The R/S
Scroll down for more posts ▼
Top 10 Most Recent News Articles
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue ReadingTop 5 Most Recently Viewed Articles
Investigation Launched into AppLovin Corporation's Alleged Fraud
Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...
Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators
Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...
Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights
Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...
Continue Reading
Understanding HCI Group's Short Interest Trends and Insights
An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...
Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients
Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...
Continue Reading